Inbrain Pharma, a company specializing in the cerebral infusion of therapeutic agents fighting against neurodegenerative diseases, announces today to benefit from the financial support of France Parkinson, a recognized association of public utility, to advance the preparation of its Phase III pivotal clinical trial. This acquisition of participation in the capital of Inbrain Pharma marks an important step for the company which offers worldwide supplementation and cerebral supplementation of missing dopamine to correct the engine condition of Parkinsonian patients in advanced stadium.
This support illustrates the recognition by France Parkinson of the therapeutic breakdown of rupture developed by Inbrain Pharma: the continuous infusion by means of A-Dopamine, a dopamine specifically designed for cerebral use because stabilized by an anaerobic solution. This therapeutic strategy aims to compensate for a precise and personalized titration the dopamine deficit. This technology, resulting from research carried out at the Lille University Hospital and the University of Lille by teachers David Devos and Caroline Moreau, Co-founders and scientific advice of the company, recently demonstrated its efficiency and its excellent tolerance in the context of the Dive-I clinical study, whose results were published in the journal Nature Medicine[1].
“The support of France Parkinson sends a strong signal, intervening at a key moment in our project requiring the federation of a certain number of actors including the community of patients, and also recalls the demanding expectations of patients for therapies really able to change their quality of life. We warmly thank France Parkinson for his confidence and his commitment to our side, ”explains Doctor Véronique Foutel, president of Inbain Pharma.
This rapprochement with France Parkinson will also open a possibility of collaboration in the field of care as well as perceived by patients as well in the finalization of phase III testing in the field of patients as well as for that already to anticipate in real life. This return of patients on such a therapeutic program is now essential and of great value because they required by all regulatory authorities, in particular for reimbursement.
“France Parkinson is committed alongside innovative actors whose projects can really change the daily life of people with Parkinson’s disease. The approach of Inbrain Pharma perfectly illustrates this ambition: it combines scientific excellence, technological innovation and will to concretely improve the quality of life for the more advanced stages of the disease, ”underlines Marie Fuzzati, PHD, scientific director of France Parkinson.
Source : InBrain Pharma
